Rxivist logo

Circulating selenium and prostate cancer risk: a Mendelian randomization analysis

By James Yarmolinsky, Carolina Bonilla, Philip C Haycock, Ryan JQ Langdon, Luca A Lotta, Claudia Langenberg, Caroline L Relton, Sarah J Lewis, David M Evans, the PRACTICAL consortium, George Davey Smith, Richard M Martin

Posted 21 Nov 2017
bioRxiv DOI: 10.1101/223248 (published DOI: 10.1093/jnci/djy081)

In the Selenium and Vitamin E Cancer Prevention Trial (SELECT), selenium supplementation (causing a median 114 μg/L increase in circulating selenium) did not lower overall prostate cancer risk, but increased risk of high-grade prostate cancer and type 2 diabetes. Mendelian randomization analysis uses genetic variants to proxy modifiable risk factors and can strengthen causal inference in observational studies. We constructed a genetic risk score comprising eleven single-nucleotide polymorphisms robustly (P < 5x10-8) associated with circulating selenium in genome-wide association studies. In a Mendelian randomization analysis of 72,729 men in the PRACTICAL Consortium (44,825 cases, 27,904 controls), 114 μg/L higher genetically-elevated circulating selenium was not associated with prostate cancer (OR: 1.01; 95% CI: 0.89-1.13). Concordant with findings from SELECT, selenium was weakly associated with advanced (including high-grade) prostate cancer (OR: 1.21; 95% CI: 0.98-1.49) and type 2 diabetes (OR: 1.18; 95% CI: 0.97-1.43; in a type 2 diabetes GWAS meta-analysis with up to 49,266 cases, 249,906 controls). Mendelian randomization mirrored the outcome of selenium supplementation in SELECT and may offer an approach for the prioritization of interventions for follow-up in large-scale randomized controlled trials.

Download data

  • Downloaded 449 times
  • Download rankings, all-time:
    • Site-wide: 85,180
    • In epidemiology: 3,726
  • Year to date:
    • Site-wide: 119,296
  • Since beginning of last month:
    • Site-wide: 118,200

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide